13 Nov

The Solidarity Trial is an international clinical trial to help find an effective treatment for COVID-19, launched by WHO and partners. It is hoped that one or more of the treatments under trial will result in improving clinical outcomes in COVID-19 patients and save lives. Other trials are on-going around the world in addition to the Solidarity Trial. 

The treatment options are: Remdesivir; Lopinavir/Ritonavir; and Lopinavir/Ritonavir with Interferon beta-1a. The treatment options were originally selected based on evidence from laboratory, animal and clinical studies. Hydroxychloroquine was originally included in the trial but this arm was stopped, as of 17 June 2020, as evidence showed it did not result in the reduction of mortality of hospitalised COVID-19 patients, when compared with standard of care. 

Over 100 countries have expressed an interest in participating in the trial and WHO is actively supporting more than 60 of them, including with the following: 

  • ethical and regulatory approvals of the WHO core protocol;
  • identification of hospitals participating in the trial;
  • training of hospital clinicians on the web-based randomization and data system;
  • shipping the trial drugs as requested by each participating country.

As of 3 June 2020, more than 3500 patients have been recruited in 35 countries, with over 400 hospitals actively recruiting patients. 

Interim trial analyses are monitored by a Global Data and Safety Monitoring Committee, which is an independent group of experts. 

Source : WHO

* The email will not be published on the website.